STING1 and cancer: For instance, recent studies have highlighted the pro-inflammatory response induced by very low doses of paclitaxel in different cancer cells, dependent on circulating cGAS and STING, leading to IFN signaling activation and enhancement of tumor immunogenicity (Serpico et al., 2023).